{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Product+1&page=2",
    "query": {
      "intervention": "Active Product 1",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Product+1&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T04:11:53.868Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02411318",
      "title": "Influence of Lifestyle Factors on Neutrophil Migration Pilot Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neutrophil Chemotactic Response"
      ],
      "interventions": [
        {
          "name": "Exercise",
          "type": "BEHAVIORAL"
        },
        {
          "name": "ProLab 200mg caffeine capsule",
          "type": "DRUG"
        },
        {
          "name": "Ethanol ingestion",
          "type": "OTHER"
        },
        {
          "name": "Glucose Tolerance Drink",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 47,
      "start_date": "2014-09-25",
      "completion_date": "2019-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-12-17",
      "last_synced_at": "2026-09-27T04:11:53.868Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02411318"
    },
    {
      "nct_id": "NCT04910568",
      "title": "A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Cevostamab",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 186,
      "start_date": "2021-07-26",
      "completion_date": "2028-12-21",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-09-27T04:11:53.868Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Irvine, California • Denver, Colorado + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04910568"
    },
    {
      "nct_id": "NCT06679582",
      "title": "Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "Luveltamab tazevibulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sutro Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "1 Day to 12 Years"
      },
      "enrollment_count": 24,
      "start_date": "2024-12-04",
      "completion_date": "2025-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-08-24",
      "last_synced_at": "2026-09-27T04:11:53.868Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06679582"
    },
    {
      "nct_id": "NCT03894540",
      "title": "Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "IPN60090",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "IPN60090 single administration",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2019-03-22",
      "completion_date": "2020-12-21",
      "has_results": true,
      "last_update_posted_date": "2022-09-13",
      "last_synced_at": "2026-09-27T04:11:53.868Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03894540"
    },
    {
      "nct_id": "NCT02057250",
      "title": "To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "RA"
      ],
      "interventions": [
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "Auto-Injector Device (AID)",
          "type": "DEVICE"
        },
        {
          "name": "Pre-filled Syringe (PFS)",
          "type": "DEVICE"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "Leflunomide",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 217,
      "start_date": "2014-03",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2017-06-20",
      "last_synced_at": "2026-09-27T04:11:53.868Z",
      "location_count": 31,
      "location_summary": "Huntsville, Alabama • Peoria, Arizona • Roseville, California + 25 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02057250"
    },
    {
      "nct_id": "NCT02978508",
      "title": "Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Scabies"
      ],
      "interventions": [
        {
          "name": "Permethrin Cream, 5%",
          "type": "DRUG"
        },
        {
          "name": "Elimite",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayne Pharma International Pty Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2016-11",
      "completion_date": "2017-05",
      "has_results": true,
      "last_update_posted_date": "2020-09-02",
      "last_synced_at": "2026-09-27T04:11:53.868Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Richland, Washington",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Richland",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02978508"
    },
    {
      "nct_id": "NCT00483496",
      "title": "Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Solar Urticaria"
      ],
      "interventions": [
        {
          "name": "Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 pigmentary 3% alone (formula RV3131A-MV1211)",
          "type": "DRUG"
        },
        {
          "name": "bisoctrizole 10% alone (formula RV3131A-MV1237)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)",
          "type": "DRUG"
        },
        {
          "name": "Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]",
          "type": "DRUG"
        },
        {
          "name": "V0096 CR vehicle (formula RV3131A-MV1197)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Orfagen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2007-09",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2017-12-22",
      "last_synced_at": "2026-09-27T04:11:53.868Z",
      "location_count": 2,
      "location_summary": "Detroit, Michigan • New York, New York",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00483496"
    },
    {
      "nct_id": "NCT05198310",
      "title": "Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "KPL-404",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kiniksa Pharmaceuticals, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 145,
      "start_date": "2021-12-14",
      "completion_date": "2024-05-06",
      "has_results": true,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-09-27T04:11:53.868Z",
      "location_count": 19,
      "location_summary": "Apple Valley, California • Covina, California • Upland, California + 15 more",
      "locations": [
        {
          "city": "Apple Valley",
          "state": "California"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05198310"
    },
    {
      "nct_id": "NCT06864988",
      "title": "4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Neovascularization Secondary to Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "4D-150 IVT (3E10 vg/eye)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EYLEA® (aflibercept) Injection 2 mg (0.05mL)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "4D Molecular Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 480,
      "start_date": "2025-03-03",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-09-27T04:11:53.868Z",
      "location_count": 91,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 79 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06864988"
    },
    {
      "nct_id": "NCT05099510",
      "title": "Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "Natrunix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "XBiotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2022-01-19",
      "completion_date": "2022-08-08",
      "has_results": true,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-09-27T04:11:53.868Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05099510"
    }
  ]
}